Detalles de la búsqueda
1.
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN.
Br J Cancer
; 130(1): 73-81, 2024 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37951974
2.
Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
BJU Int
; 134(1): 96-102, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621388
3.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol
; 20(10): 563-578, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38126311
4.
A US real-world study of treatment patterns and outcomes in localized or locally advanced prostate cancer patients.
World J Urol
; 41(12): 3535-3542, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37966506
5.
Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.
Int J Urol
; 29(6): 533-540, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35293030
6.
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.
Lancet Oncol
; 22(11): 1541-1559, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34600602
7.
Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study.
Jpn J Clin Oncol
; 50(7): 810-820, 2020 Jul 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32188988
8.
Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 20(5): 686-700, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30987939
9.
Mathematical modeling of bone marrow - peripheral blood dynamics in the disease state based on current emerging paradigms, part II.
J Theor Biol
; 460: 37-55, 2019 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30296448
10.
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
Oncologist
; 19(12): 1231-40, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25361624
11.
Influential Factors Impacting Treatment Decision-making and Decision Regret in Patients with Localized or Locally Advanced Prostate Cancer: A Systematic Literature Review.
Eur Urol Oncol
; 2024 May 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-38744587
12.
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study.
Eur Urol
; 85(6): 511-516, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38490855
13.
Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide.
Prostate Cancer Prostatic Dis
; 26(1): 156-161, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36209239
14.
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN study.
Eur J Cancer
; 193: 113290, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37708629
15.
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trial.
Asian J Androl
; 25(6): 653-661, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322621
16.
Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer.
Eur Urol Oncol
; 2023 Dec 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38072759
17.
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.
Eur J Cancer
; 162: 56-64, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34953443
18.
Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN.
Eur Urol
; 81(2): 184-192, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34916086
19.
Apalutamide for patients with metastatic castrationsensitive prostate cancer in East Asia: a subgroup analysis of the TITAN trial.
Asian J Androl
; 24(2): 161-166, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34259202
20.
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
J Clin Oncol
; 39(20): 2294-2303, 2021 07 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33914595